Annual Report 2023-2024

Solve M.E.

Letter from the President

I joined Solve M.E. as the Advocacy Manager on my birthday in 2016, and this year I took the helm as President and CEO. I am filled with gratitude and pride as I step into this role, having had the unique privilege of participating in Solve's evolution.

In my first year at Solve, I organized our first annual Advocacy Week and appropriations request letters. This was also the year in which we awarded our first Ramsay Research Grants to promising scientists in the field of ME/CFS.

Each year since, Solve's reach and impact have expanded in ways that tangibly affect our growing community. I was so honored to be part of the team that helped launch our groundbreaking YOU + ME registry in 2020. You + ME was an online observational clinical study informed by patient, caregiver, and researcher perspectives, with standardized patient-reported outcome tools, a symptom-tracking app, and free-form input.

Along with my mother, Stephanie (an ME/CFS patient since 2008), I joined the registry as soon as it opened. We were both eager to share our data in the pursuit of critical insights that could benefit all who suffer. With You + ME, my mom was able to track her health status and symptoms, connect her medical records in a secure repository, set pacing notifications to prevent post-exertional malaise (PEM), and participate in clinical research.

So this year, I celebrate the transition of You+ME to Solve Together as both a participant and as part of the Solve family.

I'm pleased to report that the You + ME Registry and Solve Together combined have over 8,500 ME/CFS and Long Covid patients and healthy participants and are supporting several exciting research studies.

Our data is a unique and powerful tool that allows researchers to uncover subtle patterns and connections, offering hope for better understanding, diagnosing, and treating conditions like ME/CFS, Long Covid, and other infection-associated chronic conditions and illnesses.

We recently saw direct evidence of this in a study published in the Autonomic Disorders section of Frontiers in Neurology. Researchers used patient data collected by Solve to identify a possible ME/CFS disease subgroup that could benefit from special attention. Researchers found a connection between ME/CFS and joint hypermobility. In multiple domains, those with joint hypermobility experienced more severe ME/CFS symptoms, including worse physical function and more pain.

The findings from this study are relevant to the day-to-day lives of patients, impacting personalized care, improved diagnosis, andfuture treatments.

We are so proud of the data collection, analyses, and studies enabled by You + ME and Solve Together. And there's so much more to come. With your continued support, we will lay the groundwork for a future where everyone affected by ME/CFS and related conditions can live fuller, healthier lives.

Emily Taylor
President & CEO
Solve M.E.

Solve Together: Transforming Your Data into Clinical Breakthroughs



Our new patient-centered data platform, Solve Together, is here!

Solve Together brings extensive advantages to the patient community and researchers. For decades, Solve has been committed to advancing research into infection-associated and fatigue-related illnesses, and empowering patients to participate in that work. This new platform builds on those efforts and allows users to track symptoms and connect with researchers, among other benefits.

Solve Together was built with the needs of individuals with ME/CFS and Long Covid in mind. Fully accessible by smartphone, the platform allows participants to connect wearables (Fitbit, Apple Watch, and others), download reports for doctor visits, link electronic health records, and expend less time and energy on participation through short, infrequent surveys and passive data collection.

Any adult in the U.S. can join Solve Together, whether they have ME/CFS, Long Covid, other post-viral fatigue-related illnesses, or *none* of these conditions (serving as "Control" participants). Joining is free, voluntary, and participants can opt out anytime.

Solve Together Goals

Solve envisions a world free of ME/CFS, Long Covid and other infection-associated chronic diseases. That's why we've created Solve Together, a data collection platform that serves as a catalyst for clinical researchers to access patients, controls, and contextual data in real-time for research that drives better diagnostics and therapeutics.

Solve Together is:

1. **Patient-Centered**
   Support personal tracking of symptoms and experiences for individual care management.
2. **Integration**
   Create a comprehensive, integrated research database with the goal of finding treatments and cures.
3. **Research-Driven**
   Help recruit for clinical studies.

Features include the ability to:

- **Track your symptoms**
- **Connect wearable devices**
- **Link electronic health records**
- **Download reports to share with providers**
- **Set pacing notifications**
- **Connect to clinical trials**

We are in the midst of a patient-driven research revolution, and people with lived experience are actively partnering with scientists to design and conduct studies that address the issues that matter most.

By joining Solve Together, users can help accelerate progress toward precise diagnostics, treatments, and one day, a cure for ME/CFS, Long Covid, and other infection-associated chronic diseases.

Fiscal Year in Review

July 2023

The FY24 Department of Defense Appropriations Report from the House of Representatives includes a Committee recommendation for $5 million to be spent on the Combat Readiness Medical Research Program. It also specifically mentions ME/CFS and Long Covid among the conditions for which the funds could be used. This separate callout was fought for by the Solve leadership and advocates during 2023 Advocacy Week.

Solve M.E. and the Long COVID Alliance (co-founded by Solve) are among dozens of organizations and experts that joined Marked By Covid in urging Congress to pass S.1489, the National Task Force on the COVID-19 Pandemic Act.

Oved Amitay, who joined Solve as President and CEO in February 2020 announces that he will be stepping down from his role.

August 2023

The Senate Appropriations Bill for FY2024 Labor, Health & Human Services, Education, & Related Agencies includes several callouts for ME/CFS and Long Covid funding specifically advocated for by Solve.

September 2023

Solve launches a new patient-centered real-world data platform, Solve Together, bringing extensive advantages to the patient community and researchers.

Tim Hsiao, PhD, joins Solve as our new Chief Scientific Officer. With more than two decades of research and scientific management experience, Tim brings his passion to strategically accelerate ME/CFS research with and for patients, their families, and the broader community that shares an interest in combating infection-associated chronic illnesses.

Solve Vice President of Advocacy and Engagement Emily Taylor co-authors "What Long Covid Investigators Can Learn From Four Decades of ME/CFS Research" in the *American Journal of Medicine*, asserting that research on ME/CFS can improve our understanding of Long Covid pathophysiology, early diagnosis, prognosis, and the discovery of effective treatments.

October 2023

Solve publishes guidelines on interactions with biopharmaceutical companies. Solve developed these guidelines rooted in a belief that all interactions between Solve M.E., industry, and the disease community should be transparent; enable trust, accountability, and shared learning; and work most efficiently and effectively toward advancing meaningful health outcomes for patients. Read Solve's "Guidelines on Interactions with Biopharmaceutical Companies" here.

Kristin Jacobson joins Solve as President and CEO, succeeding Oved Amitay. Jacobson has extensive and relevant experience as a CEO and patient advocacy leader, and brings with her over 30 years of expertise in healthcare, including executive roles in both corporate and nonprofit sectors.

November 2023

Oved Amitay represents Solve at the roundtable discussion "Advancing R&D of Long Covid & Post-Viral Diseases through Public-Private Partnerships" at the World Vaccine Congress West Coast in Santa Clara, California.

December 2023

Solve joins a broad coalition of over 80 clinicians, researchers, RECOVER PIs, and patient and disability organizations urging President Biden to address the crisis of Infection-Associated Chronic Conditions in the FY25 Budget.

Solve is awarded a $25,000 grant from Novavax in support of a three-part educational webinar series. Topics include "The Patient-Doctor Partnership: Optimally Treating People with Long Covid and ME/CFS Across the U.S.," "Changes in the Gut Microbiome in ME/CFS and Long Covid," and "Covid Vaccinations: Efficacy, Options, & Special Considerations for Chronic Illness"

January 2024

Solve submits an official statement for the Senate HELP Committee Meeting on Long Covid calling for enhanced research and community support funding, expansion of clinical care through Centers of Excellence, and improvement of quality of care through insurance coverage.

February 2024

Solve Ramsay Research Grant winners (Class of 2019) and UMass Chan Medical School viral immunologists Liisa Selin, MD, PhD, and Anna Gil, PhD publish promising results from a Solve-funded study in Brain, Behavior & Immunity Health. The paper reports two key findings that bear the potential to advance diagnostics and treatments for ME/CFS and Long Covid.

Ramsay Research Grant winner Dr. Rob C. I. Wüst (Ramsay Class of 2022) is quoted in *National Geographic* and *The New York Post* discussing results from a Solve-funded study on post-exertional malaise (PEM) which found that Long Covid patients had extreme fatigue, changes in muscle composition and widespread muscle damage.

At a June 2023 National Academies (NASEM) workshop, former Solve President Oved Amitay emphasized the ME/CFS community's needs and the role of advocacy and patient-driven data platforms like Solve Together. This month, a pre-publication report on the event is released, outlining opportunities to advance research and treatment of infection-associated chronic illnesses.

The Infection-Associated Chronic Conditions Patient Advocacy Coalition, led by Solve and partner organizations, publishes its first report with support from the CDC Foundation through the Infection Initiated Chronic Conditions Understanding and Engagement (ICUE) program. The report outlines a roadmap to strengthen support for individuals experiencing IACC through strategic collaboration.

March 2024

Solve submits comments on an NIH-wide strategic plan for autoimmune disease research, recommending the prioritization of cross-cutting, collaborative research endeavors that integrate basic, translational, clinical, and biomedical engineering approaches with a focus on diseases like ME/CFS, Long Covid, as well as the inclusion of ME/CFS cohorts in NIH research agendas.

On March 15 (Long Covid Awareness Day), Solve's VP of Advocacy and Engagement Emily Taylor is quoted by STAT News in its coverage of the push for a new office at the National Institutes of Health (NIH) to study chronic conditions that spring from infections, including ME/CFS and Long Covid. Taylor told *STAT*, "I truly believe that if we spent five years at $1 billion a year, we would have treatments for this community."

Solve announces our Advocacy Week 2024 congressional ask: "To establish a coordinating mechanism at the NIH that addresses infection-associated chronic conditions and illnesses, such as ME/CFS, Long Covid, Chronic Lyme, and POTS and other dysautonomias. This would convene researchers across specialities, streamline resources, facilitate/require patient engagement, and improve external outreach with a plan to foster collaborative research, including through clinical trials and sites."

A study published in the Autonomic Disorders section of *Frontiers in Neurology* uses data collected by Solve to identify a possible ME/CFS disease subgroup."Do People with ME/CFS and Joint Hypermobility Represent a Disease Subgroup? An Analysis Using Registry Data" is the first publication using data from Solve's You+ME registry (later transitioned to Solve Together).

April 2024

Solve M.E. Announces Emily Taylor as New President and CEO. Emily has been a key member of Solve's leadership team for more than eight years and played a critical role in securing $1.25 billion RECOVER NIH funding for Long Covid research. Emily succeeds Kristin Jacobson, who resigned after recently returning from a medical leave of absence.

Emily brings over two decades of unwavering commitment and expertise to her role as CEO of Solve M.E. With a career deeply rooted in health policy, grassroots advocacy, and community empowerment, Emily has dedicated herself to advancing medical research and patient voices in the realm of ME/CFS, Long Covid, and other infection-associated chronic conditions and illnesses.

Solve releases a new white paper "A Home for Infection-Associated Chronic Conditions and Illnesses (IACCIs) at NIH." Co-written by Solve President and CEO Emily Taylor, the white paper outlines the economic burden caused by IACCIs and the lack of appropriate NIH funding to meet the needs of those who suffer. As a possible policy solution to these problems, the co-authors recommend the establishment of a dedicated IACCI research entity at NIH.

Solve hosts our 2024 Advocacy Week virtual events, educating legislators on the emerging science and community efforts under the umbrella of IACCIs and explaining to them the need to establish a coordinating mechanism at the National Institutes of Health (NIH) to address IACCIs.

Solve celebrates the graduation of the first participants in our groundbreaking program the Long Covid Patient Leadership Advancement Network (LC-PLAN). Supported by a grant from the Chan-Zuckerburg Initiative, the LC-PLAN was designed to invest in the development of Long Covid community leaders by offering a patient-focused training curriculum tailored to prepare patients and caregivers for advisory research roles while enhancing patient engagement in Long Covid research.

May 2024

The NIH National Advisory Neurological Disorders and Stroke Council (NANDS) council approves the ME/CFS Research Roadmap, which outlines research priorities. Solve played a key role in its development through the ME/CFS Research Roadmap Working Group. Before approval, Solve also submitted public comments urging the continued inclusion of patient perspectives in future research.

In honor and recognition of May as ME Awareness Month, Solve launches our inaugural online auction Bid for Hope, raising much-needed funds for continued research and advocacy. Auction items include a 15-minute Zoom with author Meghan O'Rourke and a copy of her bestselling book, The Invisible Kingdom: Reimagining Chronic Illness, luxury vacation getaways, and a meet and greet with Olympic Gold Medalist Pam Shriver, and tickets to the U.S. Open in New York City.

In honor of World ME Day (May 12) Solve President & CEO and World ME Alliance co-chair Emily Taylor speaks at the Alliance international event "Bridging Borders – Global Voices from the World ME Alliance."

Solve hosts Dr. David Putrino and Dr. Jamie Wood (Icahn School of Medicine at Mount Sinai) for a webinar on their Long Covid research, drawing nearly 700 registrants. The event explores immune response differences in Long Covid patients and their potential role in developing new therapies. Solve Together is also referring consented users for Putrino's study comparing ME/CFS and Long Covid. The webinar is referenced in the *Nature* article, "What causes long COVID? Case builds for rogue antibodies."

Solve advocacy efforts yield another victory as the Congressionally Directed Medical Research Programs (CDMRP) program at the Department of Defense (DOD) announces a $13.1 million grant for Long Covid research. We specifically advocate with Congress for ME/CFS and Long Covid to be included in the CDMRP, providing funding to support therapeutic research related to medical threats and treatments for service members in current and future battlefield settings.

BioVie is awarded the grant to evaluate Bezisterim (NE3107) for the treatment of Long Covid. Bezisterim, an anti-inflammatory and insulin-sensitizer that permeates the blood-brain barrier, could represent a novel oral treatment targeting an underlying cause of Long Covid symptoms. This is one of the largest CDMRP grants ever awarded for a clinical trial.

Solve President Emily Taylor, Chief Scientific Officer H. Timothy Hsiao, and Director of Advancement Ilise Friedman travel to Yale School of Medicine to present an award to Center for Infection & Immunity Director and Sterling Professor Dr. Akiko Iwasaki. The leadership team also delivers an invited talk to the Iwasaki Lab on the power of the Solve Together real-world data platform to accelerate biomedical research for ME/CFS and Long Covid.

Solve Chief Scientific Officer Tim Hsiao and Solve Board Member Bill Hassler joins a delegation of patients who travel to Washington, DC to ask Senate leaders to fund Long Covid research in the NIH's $50 billion FY2025 budget.

June 2024

Solve champions three critical appropriations requests to Congress to secure funding and resources to drive research and advocacy efforts for ME/CFS, Long Covid, and other IACCIs. Our requests are for the inclusion of ME/CFS in the Peer Reviewed Medical Research Program (PRMRP), the establishment of an Office of Infection-Associated Chronic Conditions and Illnesses (IACCIs) at NIH, and the expansion of the CDC's multidisciplinary ME/CFS programs.

A new publication by 2023 Solve Ramsay Grant Award winner Dr. Deborah Duricka studies the efficacy of Stellate Ganglion Block in reducing Post-Exertional Malaise (PEM) and improving sleep and neurological function. Solve provided funding to make this journal article open access for the benefit of clinicians and patients who need it most.

A Solve-funded study by Ramsay Research Grant winners examines a root cause for ME/CFS, Long Covid, and Post-Vaccine COVID-19 Syndrome: damaged pituitary glands. Dr. Bruno Paiva (director of the Myeloma Group at the University of Navarra, Spain) and Mr. Manuel Ruiz-Pablos (research technician, medical student, and patient with ME/CFS) publish "Hypocortisolemic ASIA: a vaccine- and chronic infection–induced syndrome behind the origin of Long Covid and myalgic encephalomyelitis" (*Frontiers in Immunology*, 2024), in which they describe a new model for how infection-associated chronic illnesses develop.

Solve President and CEO Emily Taylor is quoted in *The Sick Times* article, "New NASEM reports offer broad definition, highlight the seriousness of Long Covid."

At Solve M.E.
We make breakthroughs possible
with comprehensive programs

20x ROI
$1M RAMSAY GRANTS HELPED RESEARCHERS SECURE $20M+ ADDITIONAL FUNDING

1,000,000
DATA POINTS COLLECTED FOR HEALTH RESEARCH

22
SCIENTIFIC PAPERS PUBLISHED TO DATE

2,000+
ORGANIZATIONS & INDIVIDUALS RECRUITED TO #STOPTHELONGHAUL



$100M
SECURED FOR POST-VIRAL DIAGNOSTICS AT NIH

SOLVE MEETINGS WITH CONGRESS
1,168

29,081
ELECTRONIC MESSAGES SENT DURING ADVOCACY WEEKS

37
ORIGINAL RESEARCH PROJECTS FUNDED BY RAMSAY GRANTS

$1.25BN
SECURED FOR LONG COVID RESEARCH & CLINICAL TRIALS

30
FREE WEBINARS & EVENTS

Solve Ramsay Research Grant Program

2023-24 Publications & Follow-On Funding

Solve M.E. supports research into the underlying causes of ME/CFS and Long Covid through the Ramsay Research Grant Program, an open, peer-reviewed competition for grants to support pilot studies and data analysis. Since its launch in 2016, the Ramsay Program has been successful in attracting new scientists to the field, facilitating applications for larger grants based on promising pilot data, and adding to the cumulative scientific knowledge.

RAMSAY RESEARCH GRANT PROGRAM

Below are papers published by Ramsay Program alumni from 2023-24 and information about the follow-on funding they've received this year to continue their Ramsay Grant-winning work.

Sara Ballouz, PhD

Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection (*Nat Commun*, *2024*)

Jonas Bergquist, MD, PhD

A pre- and postoperative study of patients with ME/CFS operated for foraminal stenosis (Patient-Led Research Collaborative, grant amount not disclosed)

Multi-omic approAches to Solve post-Acute COVID-19/SARS-CoV-2 Syndrome – MOSAICS (Patient-Led Research Collaborative, grant amount not disclosed)

Left-right Side-specific Neuroendocrine Signaling in Basic Neuroscience and Neurology (Swedish Research Council, 2022-01182_VR, 4,800,000 krSEK = $470,691)

Disentangling Light- and CO2-Mediated Signalling in Green Microalgae (Swedish Research Council, 2023-04397_VR, 4,000,000 krSEK = $392,369)

Improvements in Structural and Quantitative Lipidomics with Applications to Liver Cancer (Swedish Research Council, 2023-04397_VR, 3,748,000 krSEK = $367,684)

David Esteban, PhD

Microbial metabolites as disease-modifying factors in Long-COVID (Patient-Led Research Collaborative, grant amount not disclosed)

Heather Edgell, PhD

Machine learning algorithms for detection of visuomotor neural control differences in individuals with PASC and ME (*Front Hum Neurosci*, 2024)

Dawei Li, PhD

Multi-omic approAches to Solve post-Acute COVID-19/SARS-CoV-2 Syndrome – MOSAICS (Patient-Led Research Collaborative, grant amount not disclosed)

Cornell ME/CFS Collaborative Research Center (NIH, $74,750)

Vincent Lombardi, PhD

Development of humanized microbiota mouse models of ME/CFS (NIH, $437,700)

Fiona Newberry

Investigating the Human Intestinal DNA Virome and Predicting Disease-Associated Virus-Host Interactions in Severe Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (Int J Mol Sci, 2023)

Bruno Paiva, PhD, Manuel Ruiz Pablos

Epstein-Barr virus-acquired immunodeficiency in myalgic encephalomyelitis-Is it present in long COVID? (*J Transl Med*, 2023)

Aaron Ring, MD, PhD

Overcoming Melanoma Treatment Resistance with Cytokine Immunotherapy (NIH, $383,419)

Solve M.E. ADVOCACY WEEK April 15-19, 2024

250	Congressional Meetings
330	Attendees
44	States & D.C. Represented
95%	Meetings Confirmed

9	member-level meetings
76	Senate meetings
174	House meetings
155	Democrat offices
92	Republican offices
3	Independent offices

Shad Roundy, PhD

U.S.-Ireland R&D Partnership: Highly efficient magnetoelectric nano-antenna arrays with wide operational bandwidth (NSF award no. 2320320, $385,000)

Collaborative Research: Space Charge Induced Flexoelectric (SCIF) Transducers: A New Technology to Eliminate the Environmental Cost of Leaded Piezoelectric Transducers (NSF award no. 2247453, $225,000)

Avik Roy, PhD

ATG13: A new player in ME/CFS (5R21NS129021-02, $225,000)

Carmen Scheibenbogen, MD, Bhupesh Prusty, PhD

Understanding, diagnosing, and treating Myalgic encephalomyelitis/chronic fatigue syndrome - State of the art: Report of the 2nd international meeting at the Charité Fatigue Center (*Autoimmun Rev*, 2023)

Liisa Selin, PhD, Anna Gil, PhD

Identification of CD8 T-cell dysfunction associated with symptoms in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID and treatment with a nebulized antioxidant/anti-pathogen agent in a retrospective case series (*Brain Behav Immun Health*, 2023)

Altered T cell responses in Long COVID (PASC) and ME/CFS (Patient-Led Research Collaborative, grant amount not disclosed)

Immune repertoire profiling of Long COVID and ME/CFS patients (Patient-Led Research Collaborative, grant amount not disclosed)

Jennifer Stone, PhD

Systematic reviews of aetiology and risk factors of disease: a program of methodological research (National Health and Medical Research Council, $452,509)

Michael VanElzakker, PhD

Glial activation and metabolite contributions to 'brain fog' post-acute sequelae of COVID-19 (PASC) (NIH, $250,500)

Mechanisms of cognitive control impairment in ME/CFS and PASC-ME/CFS (NIH, $490,883)

Correlating neutrophil function and plasma cytokine profiles with progression of ME/CFS and Long-Covid/PASC (NIH, $210,000)

Francisco Westermeier, PhD

Endothelial dysfunction in chronic fatigue syndromes (FWF Austrian Science Fund, $308,300)

Rob Wüst, PhD

Muscle abnormalities worsen after post-exertional malaise in long COVID (*Nat Commun*, 2024)

Unraveling the pathophysiology of post-exertional malaise in Long COVID and ME/CFS (Patient-Led Research Collaborative, grant amount not disclosed)

Independent Auditor's Report

To the Board of Directors
Solve ME/CFS Initiative
Glendale, California

Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying financial statements of Solve ME/CFS Initiative (a nonprofit organization), which comprise the statement of financial position as of June 30, 2024, and the related statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the financial statements present fairly, in all material respects, the financial position of Solve ME/CFS Initiative as of June 30, 2024, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Solve ME/CFS Initiative and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Solve ME/CFS Initiative's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Solve ME/CFS Initiative's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Solve ME/CFS Initiative 's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Report on Summarized Comparative Information

We have previously audited Solve ME/CFS Initiative's June 30, 2023 financial statements, and we expressed an unmodified audit opinion on those audited financial statements in our report dated September 27, 2024. In our opinion, the summarized comparative information presented herein as of and for the year ended June 30, 2023, is consistent, in all material respects, with the audited financial statements from which it has been derived.

Lewis Sharpstone & Co.

Lewis Sharpstone & Co.
5850 Canoga Avenue, Suite 400
Woodland Hills, California 91367
March 6, 2025



In honor of ME Awareness Day, Emily Taylor speaks at the World ME Alliance international event "Bridging Borders – Global Voices from the World ME Alliance."

Solve Chief Scientific Officer Tim Hsiao, Director of Advancement Ilise Friedman, Dr. Akiko Iwasaki, and Solve President Emily Taylor.

Solve Chief Scientific Officer Tim Hsiao and Solve Board Member Bill Hassler join a delegation of patient advocates visiting Senators in Washington, D.C.

Statement of Financial Position

June 30, 2024

(With Comparative Totals as of June 30, 2023)

ASSETS	2024	2023
Cash and cash equivalents	$ 246,884	$ 222,501
Investments	628,974	1,567,345
Contributions and grants receivable	141,372	326,648
Prepaid expenses and other assets	54,313	71,582
Property and Equipment, net	2,720	-
Total Assets	$ 1,074,263	$ 2,188,076
LIABILITIES AND NET ASSETS		
LIABILITIES		
Accounts payable and accrued expenses	$ 313,990	$ 527,903
Total Liabilities	313,990	527,903
NET ASSETS		
Without donor restrictions	649,931	1,322,430
With donor restrictions	110,342	337,743
Total Net Assets	760,273	1,660,173
Total Liabilities and Net Assets	$ 1,074,263	$ 2,188,076

Statement of Activities

Year Ended June 30, 2024

(With Comparative Totals for the Year Ended June 30, 2023)

	2024			2023
	Without Donor Restrictions	With Donor Restrictions	Total	Total
REVENUES AND SUPPORT				
Contributions and grants	$ 1,529,770	$ 381,757	$ 1,911,527	$ 1,988,897
In-kind contributions	197,39	-	197,339	174,087
Investment income	33,979	1,600	35,579	54,951
Net assets released from restrictions	610,758	(610,758)	-	-
Total Revenues and Support	2,371,846	(227,401)	2,144,445	2,217,935
EXPENSES				
Program services				
Research	906,316	-	906,316	1,262,558
Advocacy and communication	850,965	-	850,965	1,641,341
Total program services	1,757,281	-	1,757,281	2,903,899
Management and general	693,305	-	693,305	459,919
Fundraising	593,759	-	593,759	664,860
Total Expenses	3,044,345	-	3,044,345	4,028,678
CHANGE IN NET ASSETS	(672,499)	(227,401)	(899,900)	(1,810,743)
NET ASSETS, Beginning of Year	1,322,430	337,743	1,660,173	3,470,916
NET ASSETS, End of Year	$ 649,931	$ 110,342	$ 760,273	$ 1,660,173

Solve M.E. Team

Board of Directors
Each board member has a personal connection to infection-associated diseases. They either themselves live with these diseases, have a loved one who suffers, or care for people who are impacted.

Cynthia Adinig, Alexandria, VA

Michael Atherton, Treasurer Arlington, VA

Joseph Barerra, Newport, CA

Kenya Beckman, Los Angeles, CA

Victoria Boies, Chicago, IL

Stewart Gittelman, Lloyd Neck, NY

William Hassler, Esq. Washington, DC

Carol Head, Los Angeles, CA

Gurdyal Kalsi, MD, MFPM (Hon) Baltimore, MD

Rona E. Kramer, Olney, MD

Barbara Lubash, Vice-Chair, Corona Del Mar, CA

John Nicols, Chair, Redwood City, CA

Amrit Shahzad, San Diego, CA

Rick Sprout, Secretary, Fairfax, VA

Janice Stanton, Harrison, NY

Staff

Afifah Ayub, Clinical Data Coordinator

Ilise Friedman, Director of Advancement

Erin Gary, Manager of Human Resources and Operations

Tim Hsiao, Chief Scientific Officer, Head of Research Strategy and Alliances

Karman Kregloe, Associate Director of Communications

Amanda Martin, Engagement Manager

Elissa Regan, Associate Director of Advancement

Emily Taylor, President and CEO

Monique Wike, Executive and Advocacy Manager

Research Advisory Council (RAC)

Anthony Komaroff, MD
Simcox-Clifford-Higby Professor of Medicine, Harvard Medical School

Susan Levine, MD
Founder, Medical Office of Susan M. Levine

Maureen Hanson, PhD
Liberty Hyde Bailey Professor, Cornell University

Peter Rowe, MD
Professor of Pediatrics, Johns Hopkins University School of Medicine

Lucinda Bateman, MD
Founder & Chief Medical Officer, Bateman Horne Center

Rochelle Joslyn, PhD
Immunologist, Independent Consultant

Sheila Stewart, PhD
Associate Professor, Washington University School of Medicine

Daan Archer, MBA, MSc
Technology Entrepreneur

John Nicols, MBA
Biotechnology Industry Advisor;
CEO, Codexis Inc. ('12-'22)

Morgan Fairchild,
Actress and Activist

ExOfficioMember
Oved Amitay
President & CEO, Solve M.E.

Solve M.E.

350 N Glendale Ave.
Suite B #368
Glendale, CA 91206

704-364-0016

SolveCFS@SolveCFS.org

www.SolveME.org

EIN: 56-1683450